Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Core Insights - Atossa Therapeutics has appointed CORE IR to enhance investor awareness and strengthen shareholder engagement [1][2] - The collaboration aims to broaden the company's reach to both institutional and retail audiences [1] - CORE IR will provide a comprehensive suite of investor relations services, including strategic messaging and investor outreach [2] Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on innovative approaches to breast cancer treatment and prevention [3] - The company's lead product candidate, (Z)-endoxifen, is designed for use across the breast cancer spectrum, including risk-reduction and treatment in various settings [3] - Atossa is committed to advancing clinical research programs to improve patient outcomes and create sustainable value for shareholders [3]